Logo

Goldman Sachs

Adaptive Biotechnologies to Keep MRD and Immune Medicine Businesses Following Strategic Review

The Seattle-based firm is restructuring to increase each unit's independence by allocating them resources and separating their reporting.

Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium

While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.

Myriad Genetics to Raise $110M in Public Stock Offering

The Salt Lake City-based genetic testing and precision medicine company is offering 6,470,588 shares of its common stock at a public offering price of $17 per share.

PerkinElmer Reaches Deal for $1.5B Credit Facility

The agreement is for a new credit facility, which replaces one from 2019 that provided for a $1 billion unsecured revolving credit facility.

PerkinElmer Enters $500M Credit Facility

The proceeds will be used to pay, in part, PerkinElmer's $5.25B acquisition of BioLegend, announced last month.